首页 > 最新文献

Journal of Clinical and Translational Endocrinology最新文献

英文 中文
Simple prediction model for vitamin D deficiency in women with osteoporosis or risk factors for osteoporosis in Thailand 泰国骨质疏松症妇女维生素D缺乏或骨质疏松症危险因素的简单预测模型。
IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
Journal of Clinical and Translational Endocrinology
Pub Date : 2024-12-01 Epub Date: 2024-11-22 DOI: 10.1016/j.jcte.2024.100377
Tidaporn Mullikapipat , Natee Dumrongwongsuwinai , Orawin Vallibhakara , Sasivimol Rattanasiri , Sakda Arj-Ong Vallibhakara , Wiwat Wajanavisit , Boonsong Ongphiphadhanakul , Hataikarn Nimitphong

Introduction

In Thailand, the assessment of vitamin D status by measuring 25-hydroxyvitamin D[25(OH)D] levels in individuals at risk for osteoporosis is constrained by limited facilities and high costs. This study aimed to create a clinical model for predicting vitamin D deficiency in women with osteoporosis or risk factors for osteoporosis.

Materials and Methods

This was a cross-sectional study of 490 women. All participants had 25(OH)D levels measured. A questionnaire was used to assess factors related to vitamin D status. Vitamin D deficiency was defined as 25(OH)D levels < 30 ng/mL. Logistic regression analyses were conducted to investigate predictors of vitamin D deficiency. In the model, odds ratios (ORs) were converted into simple scores. The optimal cutoff for women at a high risk of vitamin D deficiency was established. Internal validation was assessed using a Bootstrap.

Results

Sixty percent had vitamin D deficiency. The final model for predicting vitamin D deficiency consisted of a body mass index ≥ 25 kg/m2 (OR:1.15), lack of exercise (OR:1.59), exercise 1–2 times/week (OR:1.40), sunlight exposure < 15 min/day (OR:1.70), no vitamin D supplementation (OR:8.76), and vitamin D supplementation of 1–20,000 IU/week (OR:2.31). The area under the curve was 0.747. At a cutoff of 6.6 in total risk score (range 4–13.6), the model predicted vitamin D deficiency with a sensitivity of 71.9 % and a specificity of 65.3 %. The internal validation by Bootstrap revealed a ROC of 0.737.

Conclusions

In women at risk of osteoporosis, a simple risk score can identify individuals with a high risk of vitamin D deficiency. These women could benefit from vitamin D supplementation without requiring 25(OH)D measurements.
在泰国，由于设备有限和费用高昂，通过测量有骨质疏松风险个体的25-羟基维生素D[25(OH)D]水平来评估维生素D状态受到限制。本研究旨在建立一种临床模型来预测骨质疏松症妇女维生素D缺乏症或骨质疏松症的危险因素。材料和方法：这是一项涉及490名女性的横断面研究。所有参与者都测量了25(OH)D水平。一份调查问卷用于评估与维生素D状况相关的因素。维生素D缺乏症被定义为25(OH)D水平结果：60%的人缺乏维生素D。预测维生素D缺乏的最终模型包括体重指数≥25 kg/m2 （OR:1.15）、缺乏运动（OR:1.59）、每周运动1-2次（OR:1.40）、阳光照射。结论：在有骨质疏松症风险的女性中，简单的风险评分可以识别出维生素D缺乏的高风险个体。这些妇女可以从补充维生素D中获益，而不需要测量25(OH)D。
{"title":"Simple prediction model for vitamin D deficiency in women with osteoporosis or risk factors for osteoporosis in Thailand","authors":"Tidaporn Mullikapipat ,&nbsp;Natee Dumrongwongsuwinai ,&nbsp;Orawin Vallibhakara ,&nbsp;Sasivimol Rattanasiri ,&nbsp;Sakda Arj-Ong Vallibhakara ,&nbsp;Wiwat Wajanavisit ,&nbsp;Boonsong Ongphiphadhanakul ,&nbsp;Hataikarn Nimitphong","doi":"10.1016/j.jcte.2024.100377","DOIUrl":"10.1016/j.jcte.2024.100377","url":null,"abstract":"<div><h3>Introduction</h3><div>In Thailand, the assessment of vitamin D status by measuring 25-hydroxyvitamin D[25(OH)D] levels in individuals at risk for osteoporosis is constrained by limited facilities and high costs. This study aimed to create a clinical model for predicting vitamin D deficiency in women with osteoporosis or risk factors for osteoporosis.</div></div><div><h3>Materials and Methods</h3><div>This was a cross-sectional study of 490 women. All participants had 25(OH)D levels measured. A questionnaire was used to assess factors related to vitamin D status. Vitamin D deficiency was defined as 25(OH)D levels &lt; 30 ng/mL. Logistic regression analyses were conducted to investigate predictors of vitamin D deficiency. In the model, odds ratios (ORs) were converted into simple scores. The optimal cutoff for women at a high risk of vitamin D deficiency was established. Internal validation was assessed using a Bootstrap.</div></div><div><h3>Results</h3><div>Sixty percent had vitamin D deficiency. The final model for predicting vitamin D deficiency consisted of a body mass index ≥ 25 kg/m<sup>2</sup> (OR:1.15), lack of exercise (OR:1.59), exercise 1–2 times/week (OR:1.40), sunlight exposure &lt; 15 min/day (OR:1.70), no vitamin D supplementation (OR:8.76), and vitamin D supplementation of 1–20,000 IU/week (OR:2.31). The area under the curve was 0.747. At a cutoff of 6.6 in total risk score (range 4–13.6), the model predicted vitamin D deficiency with a sensitivity of 71.9 % and a specificity of 65.3 %. The internal validation by Bootstrap revealed a ROC of 0.737.</div></div><div><h3>Conclusions</h3><div>In women at risk of osteoporosis, a simple risk score can identify individuals with a high risk of vitamin D deficiency. These women could benefit from vitamin D supplementation without requiring 25(OH)D measurements.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100377"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics of Ketosis Prone Diabetes: Evaluating diagnosis and management practices in a real-life setting 酮症易发糖尿病的临床特征：评估现实生活中的诊断和管理方法
IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
Journal of Clinical and Translational Endocrinology
Pub Date : 2024-12-01 Epub Date: 2024-10-02 DOI: 10.1016/j.jcte.2024.100371
Zunera Tariq , Anusha Sinha , Gina Shokry , Kelly Moors , Sai Sripad Kodukula , Carmella Evans-Molina , Zeb Ijaz Saeed
{"title":"Clinical characteristics of Ketosis Prone Diabetes: Evaluating diagnosis and management practices in a real-life setting","authors":"Zunera Tariq ,&nbsp;Anusha Sinha ,&nbsp;Gina Shokry ,&nbsp;Kelly Moors ,&nbsp;Sai Sripad Kodukula ,&nbsp;Carmella Evans-Molina ,&nbsp;Zeb Ijaz Saeed","doi":"10.1016/j.jcte.2024.100371","DOIUrl":"10.1016/j.jcte.2024.100371","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100371"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142426065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands 治疗 1 型糖尿病的生物人工胰腺：荷兰医疗保健专业人员的观点
IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
Journal of Clinical and Translational Endocrinology
Pub Date : 2024-12-01 Epub Date: 2024-10-17 DOI: 10.1016/j.jcte.2024.100372
Dide de Jongh , Eline Bunnik , Behiye Ozcan , Robert Zietse , Emma Massey , VANGUARD consortium

Aims

Healthcare professionals are relevant stakeholders because of their gatekeeper role in the clinic. This study aims to explore their perspectives on the potential future clinical implementation of the bio-artificial pancreas (BAP) for people with type 1 diabetes, and suitable target groups.

Methods

Semi-structured interviews were conducted with 17 healthcare professionals, including endocrinologists, nurses, and pancreas transplant surgeons. Inclusion was stopped once data saturation was reached. The audiotaped interviews were transcribed verbatim. Qualitative content analysis using an inductive approach was conducted to develop themes within a coding framework.

Results

Three main themes emerged: (1) hoped-for benefits, which included improved clinical outcomes, enhanced sense of normality, reduced mental burden for patients and their significant others, greater societal participation, and lower costs; (2) concerns, which included safety and effectiveness, inequitable access, accurate information, control over self-management, and organizational challenges; and (3) allocating the BAP during initial implementation, which included prioritizing people who lack effective treatment options, people with mental health issues, and vulnerable people.

Conclusions

The results of this study are important for researchers and practitioners involved in the development of the BAP, so that they can align its design and the process of clinical implementation with healthcare professionals’ perspectives.
目的 医护人员是相关利益方，因为他们在临床中扮演着把关人的角色。本研究旨在探讨他们对生物人工胰腺 (BAP) 未来在 1 型糖尿病患者中的潜在临床应用以及合适目标群体的看法。方法对 17 名医疗保健专业人员进行了半结构式访谈，其中包括内分泌科医生、护士和胰腺移植外科医生。一旦数据达到饱和，即停止纳入。访谈录音逐字记录。采用归纳法进行定性内容分析，在编码框架内形成主题。结果出现了三大主题：(1) 希望获得的益处，包括改善临床结果、增强正常感、减轻患者及其重要他人的精神负担、扩大社会参与以及降低成本；(2) 关注的问题，包括安全性和有效性、不公平的获取途径、准确的信息、对自我管理的控制以及组织方面的挑战；(3) 在初步实施过程中对 BAP 的分配，包括优先考虑缺乏有效治疗选择的人、有精神健康问题的人以及弱势人群。结论本研究的结果对于参与制定《最佳治疗方案》的研究人员和从业人员非常重要，这样他们就可以根据医护专业人员的观点调整方案的设计和临床实施过程。
{"title":"The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands","authors":"Dide de Jongh ,&nbsp;Eline Bunnik ,&nbsp;Behiye Ozcan ,&nbsp;Robert Zietse ,&nbsp;Emma Massey ,&nbsp;VANGUARD consortium","doi":"10.1016/j.jcte.2024.100372","DOIUrl":"10.1016/j.jcte.2024.100372","url":null,"abstract":"<div><h3>Aims</h3><div>Healthcare professionals are relevant stakeholders because of their gatekeeper role in the clinic. This study aims to explore their perspectives on the potential future clinical implementation of the bio-artificial pancreas (BAP) for people with type 1 diabetes, and suitable target groups.</div></div><div><h3>Methods</h3><div>Semi-structured interviews were conducted with 17 healthcare professionals, including endocrinologists, nurses, and pancreas transplant surgeons. Inclusion was stopped once data saturation was reached. The audiotaped interviews were transcribed verbatim. Qualitative content analysis using an inductive approach was conducted to develop themes within a coding framework.</div></div><div><h3>Results</h3><div>Three main themes emerged: (1) hoped-for benefits, which included improved clinical outcomes, enhanced sense of normality, reduced mental burden for patients and their significant others, greater societal participation, and lower costs; (2) concerns, which included safety and effectiveness, inequitable access, accurate information, control over self-management, and organizational challenges; and (3) allocating the BAP during initial implementation, which included prioritizing people who lack effective treatment options, people with mental health issues, and vulnerable people.</div></div><div><h3>Conclusions</h3><div>The results of this study are important for researchers and practitioners involved in the development of the BAP, so that they can align its design and the process of clinical implementation with healthcare professionals’ perspectives.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100372"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142527368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes” [J. Clin. Translat. Endoc. 36C (2024) 100343] semaglutide对肾移植后2型糖尿病或移植后糖尿病患者的安全性和疗效"[J. Clin. Translat. Endoc. 36C (2024) 100343]的更正
IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
Journal of Clinical and Translational Endocrinology
Pub Date : 2024-12-01 Epub Date: 2024-07-09 DOI: 10.1016/j.jcte.2024.100360
Moeber Mohammed Mahzari , Omar Buraykan Alluhayyan , Mahdi Hamad Almutairi , Mohammed Abdullah Bayounis , Yazeed Hasan Alrayani , Amir A. Omair , Awad Saad Alshahrani
{"title":"Corrigendum to “Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes” [J. Clin. Translat. Endoc. 36C (2024) 100343]","authors":"Moeber Mohammed Mahzari ,&nbsp;Omar Buraykan Alluhayyan ,&nbsp;Mahdi Hamad Almutairi ,&nbsp;Mohammed Abdullah Bayounis ,&nbsp;Yazeed Hasan Alrayani ,&nbsp;Amir A. Omair ,&nbsp;Awad Saad Alshahrani","doi":"10.1016/j.jcte.2024.100360","DOIUrl":"10.1016/j.jcte.2024.100360","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100360"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141712363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PCSK7 levels in women with and without PCOS PCOS患者和非PCOS女性的PCSK7水平
IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
Journal of Clinical and Translational Endocrinology
Pub Date : 2024-12-01 Epub Date: 2024-11-28 DOI: 10.1016/j.jcte.2024.100376
Stephen L. Atkin , Alexandra E Butler , Tannaz Jamialahmadi , Amirhossein Sahebkar
{"title":"PCSK7 levels in women with and without PCOS","authors":"Stephen L. Atkin ,&nbsp;Alexandra E Butler ,&nbsp;Tannaz Jamialahmadi ,&nbsp;Amirhossein Sahebkar","doi":"10.1016/j.jcte.2024.100376","DOIUrl":"10.1016/j.jcte.2024.100376","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100376"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eating habits and carotenoid skin content among children based on their attendance at the school meals: A cross-sectional pilot study 儿童的饮食习惯和类胡萝卜素表皮含量与他们在学校就餐的情况有关：横断面试点研究
IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
Journal of Clinical and Translational Endocrinology
Pub Date : 2024-12-01 Epub Date: 2024-11-23 DOI: 10.1016/j.jcte.2024.100378
Giovanna Caparello , Fabrizio Ceraudo , Francesca Meringolo , Giuseppina Augimeri , Giuseppe Morino , Daniela Bonofiglio

Objective

The promotion of a healthy diet, such as the Mediterranean Diet (MD), among childhood is of a particular importance, since eating behaviors learned early in life have been shown to be maintained into adolescence and adulthood. The most efficient intervention in childhood is the active involvement of the schools.

Design

The aim of this study was to evaluate the adherence to the MD model and the skin carotenoid levels among children divided by their school lunch attendance.

Methods

This cross-sectional study involved 132 pupils (64 girls and 68 boys), divided between children who ate lunch at school (44%) and at home (56%). The children who had meals provided by the school participated in activities promoting the health benefits of fruits and vegetables. All participants underwent anthropometric measurements and assessment of the MD adherence and the physical activity using KIDMED and PAQ-C questionnaires, respectively, and skin carotenoid content using the Veggie Meter®.

Results

We found mean KIDMED and PAQ-C scores, while skin carotenoid content was below the normal range in our population sample. Interestingly, children who ate lunch provided by the school had significantly higher carotenoid scores with respect to those who had lunch at home (p = 0.005). In multiple regression analyses, we found that carotenoid scores were positively influenced by gender (p = 0.03), school lunch attendance (p = 0.01) and daily vegetable consumption (p = 0.0002) in our children population sample.

Conclusions

Our results suggest the importance of promoting a healthy lifestyle at the school to improve eating habits during childhood as a strategy for disease prevention across the lifespan.
目的 在儿童时期推广健康饮食，如地中海饮食（Mediterranean Diet，MD），具有特别重要的意义，因为在生命早期学会的饮食行为已被证明可以保持到青春期和成年期。这项研究的目的是评估儿童对地中海饮食模式的坚持情况以及皮肤类胡萝卜素水平，并根据他们在学校吃午餐的情况进行划分。方法这项横断面研究涉及 132 名学生（64 名女孩和 68 名男孩），分为在学校吃午餐的儿童（44%）和在家吃午餐的儿童（56%）。在学校用餐的儿童参加了宣传水果和蔬菜对健康益处的活动。所有参与者都接受了人体测量，并分别使用 KIDMED 和 PAQ-C 问卷对坚持 MD 和体育锻炼情况进行了评估，还使用 Veggie Meter® 对皮肤类胡萝卜素含量进行了评估。有趣的是，与在家吃午餐的儿童相比，吃学校提供的午餐的儿童类胡萝卜素得分明显更高（p = 0.005）。在多元回归分析中，我们发现类胡萝卜素得分受性别（p = 0.03）、学校午餐就餐率（p = 0.01）和每日蔬菜摄入量（p = 0.0002）的积极影响。
{"title":"Eating habits and carotenoid skin content among children based on their attendance at the school meals: A cross-sectional pilot study","authors":"Giovanna Caparello ,&nbsp;Fabrizio Ceraudo ,&nbsp;Francesca Meringolo ,&nbsp;Giuseppina Augimeri ,&nbsp;Giuseppe Morino ,&nbsp;Daniela Bonofiglio","doi":"10.1016/j.jcte.2024.100378","DOIUrl":"10.1016/j.jcte.2024.100378","url":null,"abstract":"<div><h3>Objective</h3><div>The promotion of a healthy diet, such as the Mediterranean Diet (MD), among childhood is of a particular importance, since eating behaviors learned early in life have been shown to be maintained into adolescence and adulthood. The most efficient intervention in childhood is the active involvement of the schools.</div></div><div><h3>Design</h3><div>The aim of this study was to evaluate the adherence to the MD model and the skin carotenoid levels among children divided by their school lunch attendance.</div></div><div><h3>Methods</h3><div>This cross-sectional study involved 132 pupils (64 girls and 68 boys), divided between children who ate lunch at school (44%) and at home (56%). The children who had meals provided by the school participated in activities promoting the health benefits of fruits and vegetables. All participants underwent anthropometric measurements and assessment of the MD adherence and the physical activity using KIDMED and PAQ-C questionnaires, respectively, and skin carotenoid content using the Veggie Meter®.</div></div><div><h3>Results</h3><div>We found mean KIDMED and PAQ-C scores, while skin carotenoid content was below the normal range in our population sample. Interestingly, children who ate lunch provided by the school had significantly higher carotenoid scores with respect to those who had lunch at home (<em>p = 0.005</em>). In multiple regression analyses, we found that carotenoid scores were positively influenced by gender (<em>p = 0.03</em>), school lunch attendance (<em>p = 0.01</em>) and daily vegetable consumption (<em>p = 0.0002</em>) in our children population sample.</div></div><div><h3>Conclusions</h3><div>Our results suggest the importance of promoting a healthy lifestyle at the school to improve eating habits during childhood as a strategy for disease prevention across the lifespan.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100378"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review 胰高血糖素样肽1受体激动剂治疗囊性纤维化相关糖尿病并发肥胖症：系列病例和文献综述
IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
Journal of Clinical and Translational Endocrinology
Pub Date : 2024-12-01 Epub Date: 2024-11-07 DOI: 10.1016/j.jcte.2024.100375
Ammar Ahmed , Anvitha Ankireddypalli , Tasma Harindhanavudhi , Antoinette Moran , Amir Moheet
Cystic fibrosis-related diabetes (CFRD) is the most common non-pulmonary comorbidity in people with cystic fibrosis (CF). Current guidelines recommend insulin therapy as the treatment of choice for people with CFRD. In the past, obesity and overweight were uncommon in individuals with CF. However, in recent years, advancements in CF therapies have led to a significant increase in the prevalence of overweight and obesity within this population. Glucagon-like peptide1 receptor agonist (GLP-1 RA) therapies could potentially improve glycemic control in people with CF by increasing insulin secretion, slowing gastric emptying, and promoting weight loss through central appetite suppression, which in turn can enhance insulin sensitivity. We report, for the first time, five cases of individuals with CFRD complicated by obesity treated with GLP 1-RA for at least two years. With GLP 1-RA therapy, 4 out of 5 individuals exhibited weight reduction ranging from 7% to 19% over two years, while forced expiratory volume in 1 s (FEV1)/predicted FEV1 % remained stable or improved in all cases. The impact on glycemic control was variable. Insulin requirements either reduced or remained stable in all five cases. Overall, GLP-1 RA was well tolerated in this case series; one individual discontinued the medication after two years of therapy due to poor appetite and nausea.
囊性纤维化相关糖尿病（CFRD）是囊性纤维化（CF）患者最常见的非肺合并症。现行指南建议将胰岛素治疗作为囊性纤维化相关糖尿病患者的首选治疗方法。过去，肥胖和超重在 CF 患者中并不常见。然而，近年来，CF疗法的进步导致这一人群中超重和肥胖的发生率显著增加。胰高血糖素样肽1受体激动剂（GLP-1 RA）疗法可通过增加胰岛素分泌、减缓胃排空、抑制中枢食欲促进体重减轻，进而增强胰岛素敏感性，从而改善CF患者的血糖控制。我们首次报道了五例因肥胖而并发 CFRD 的患者，他们接受了至少两年的 GLP 1-RA 治疗。通过 GLP 1-RA 治疗，5 人中有 4 人的体重在两年内下降了 7% 到 19%，而所有病例的 1 秒用力呼气容积 (FEV1) / 预测 FEV1 % 均保持稳定或有所改善。对血糖控制的影响各不相同。所有五个病例的胰岛素需求量都有所减少或保持稳定。总体而言，本系列病例对 GLP-1 RA 的耐受性良好；其中一人在接受治疗两年后因食欲不振和恶心而停药。
{"title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review","authors":"Ammar Ahmed ,&nbsp;Anvitha Ankireddypalli ,&nbsp;Tasma Harindhanavudhi ,&nbsp;Antoinette Moran ,&nbsp;Amir Moheet","doi":"10.1016/j.jcte.2024.100375","DOIUrl":"10.1016/j.jcte.2024.100375","url":null,"abstract":"<div><div>Cystic fibrosis-related diabetes (CFRD) is the most common non-pulmonary comorbidity in people with cystic fibrosis (CF). Current guidelines recommend insulin therapy as the treatment of choice for people with CFRD. In the past, obesity and overweight were uncommon in individuals with CF. However, in recent years, advancements in CF therapies have led to a significant increase in the prevalence of overweight and obesity within this population. Glucagon-like peptide1 receptor agonist (GLP-1 RA) therapies could potentially improve glycemic control in people with CF by increasing insulin secretion, slowing gastric emptying, and promoting weight loss through central appetite suppression, which in turn can enhance insulin sensitivity. We report, for the first time, five cases of individuals with CFRD complicated by obesity treated with GLP 1-RA for at least two years. With GLP 1-RA therapy, 4 out of 5 individuals exhibited weight reduction ranging from 7% to 19% over two years, while forced expiratory volume in 1 s (FEV1)/predicted FEV1 % remained stable or improved in all cases. The impact on glycemic control was variable. Insulin requirements either reduced or remained stable in all five cases. Overall, GLP-1 RA was well tolerated in this case series; one individual discontinued the medication after two years of therapy due to poor appetite and nausea.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100375"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142655723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC) 分化型甲状腺癌（DTC）患者在正确的时间使用正确的药物并进行正确的检查
IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
Journal of Clinical and Translational Endocrinology
Pub Date : 2024-12-01 Epub Date: 2024-10-31 DOI: 10.1016/j.jcte.2024.100373
Dario de Biase , Andrea Repaci , Maria Concetta Nigro , Thais Maloberti , Francesca Carosi , Maria A. Pantaleo , Giovanni Tallini , Margherita Nannini
Thanks to the identification of crucial molecular pathways, the therapeutic landscape for advanced differentiated thyroid tumors (DTCs) has significantly improved during the last ten years. The therapeutic scenario has been greatly impacted by the discovery of mutually exclusive gene changes in the MAPK and PI3K/AKT pathways, such as RET or NTRK fusions and pathogenic mutations of the BRAF and RAS genes. Indeed, multi-kinase inhibitors and selective inhibitors have demonstrated outstanding efficacy for radioactive iodine-refractory (RAI-R) drug treatment, with overall response rates reaching up to 86%. Thus, for RAI-R DTCs, routine molecular testing for actionable gene alterations is now essential, for choosing the right therapy for the right patient.
Additionally, tumor genotyping also allows to identify a subset of patients with worse prognosis disease, which may deserve a tailored clinical management. Thus, the right test should also include non-driver TERT, TP53, PIK3CA, and other mutations of aggressiveness, with the aim of a molecular-based risk stratification. Therefore, tumor genotyping should be considered in the diagnostic work-up of metastatic DTC patients or with highly aggressive histological features, in order to give the right drug for the right patient at the right time.
由于关键分子途径的确定，晚期分化甲状腺肿瘤（dtc）的治疗前景在过去十年中有了显着改善。MAPK和PI3K/AKT通路中相互排斥的基因变化的发现，如RET或NTRK融合以及BRAF和RAS基因的致病性突变，极大地影响了治疗方案。事实上，多激酶抑制剂和选择性抑制剂在放射性难治碘（RAI-R）药物治疗中表现出了出色的疗效，总有效率高达86%。因此，对于rar - r dtc，常规分子检测可操作的基因改变现在是必要的，为正确的患者选择正确的治疗方法。此外，肿瘤基因分型还允许识别预后较差的患者亚群，这可能需要量身定制的临床管理。因此，正确的检测还应包括非驱动TERT、TP53、PIK3CA和其他侵袭性突变，目的是基于分子的风险分层。因此，在转移性DTC患者或具有高度侵袭性组织学特征的患者的诊断工作中，应考虑肿瘤基因分型，以便在正确的时间给正确的患者正确的药物。
{"title":"The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC)","authors":"Dario de Biase ,&nbsp;Andrea Repaci ,&nbsp;Maria Concetta Nigro ,&nbsp;Thais Maloberti ,&nbsp;Francesca Carosi ,&nbsp;Maria A. Pantaleo ,&nbsp;Giovanni Tallini ,&nbsp;Margherita Nannini","doi":"10.1016/j.jcte.2024.100373","DOIUrl":"10.1016/j.jcte.2024.100373","url":null,"abstract":"<div><div>Thanks to the identification of crucial molecular pathways, the therapeutic landscape for advanced differentiated thyroid tumors (DTCs) has significantly improved during the last ten years. The therapeutic scenario has been greatly impacted by the discovery of mutually exclusive gene changes in the MAPK and PI3K/AKT pathways, such as <em>RET</em> or <em>NTRK</em> fusions and pathogenic mutations of the <em>BRAF</em> and <em>RAS</em> genes. Indeed, multi-kinase inhibitors and selective inhibitors have demonstrated outstanding efficacy for radioactive iodine-refractory (RAI-R) drug treatment, with overall response rates reaching up to 86%. Thus, for RAI-R DTCs, routine molecular testing for actionable gene alterations is now essential, for choosing the right therapy for the right patient.</div><div>Additionally, tumor genotyping also allows to identify a subset of patients with worse prognosis disease, which may deserve a tailored clinical management. Thus, the right test should also include non-driver <em>TERT</em>, <em>TP53</em>, <em>PIK3CA</em>, and other mutations of aggressiveness, with the aim of a molecular-based risk stratification. Therefore, tumor genotyping should be considered in the diagnostic work-up of metastatic DTC patients or with highly aggressive histological features, in order to give the right drug for the right patient at the right time.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100373"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143161734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study 基于增量素的药物与 2 型糖尿病患者罹患胆管癌风险之间的关系：大型人群匹配队列研究
IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
Journal of Clinical and Translational Endocrinology
Pub Date : 2024-12-01 Epub Date: 2024-09-18 DOI: 10.1016/j.jcte.2024.100370
Arunkumar Krishnan , Carolin V. Schneider , Hendrik-Tobias Arkenau , Ezequiel Matias Mauro , Alejandro Forner , W. Scott Butsch , Declan Walsh , Saleh A. Alqahtani

Aim

To examine the association between the use of incretin-based drugs [glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4Is)] and the risk of cholangiocarcinoma (CCA) in the United States.

Methods

This large population-based, retrospective cohort study using the TriNetX datasets included adult patients with type 2 diabetes mellitus (T2DM) who were new users of GLP-1RAs, DPP-4Is, or other second- or third-line antidiabetic drugs between 2010 and 2021. The primary outcome was the incidence of CCA.

Results

A total of 3,816,071 patients were included (mean age, 61.4 years, female, 49.3 %). A 51 % and 23 % risk reduction in CCA after 1 year of exposure to GLP-1RAs (hazard ratio 0.49; 95 % CI 0.40–0.60) and DPP4Is (0.77, 95 % CI 0.67–0.90), respectively compared to new second-or third-line users. Results were consistent at 3, 5, and 7 years of follow-up (0.66, 0.71, and 0.72 for GLP-1RAs and 0.84, 0.87, and 0.85 for DPP-4Is, respectively). Compared to new metformin users, GLP-1RA users were associated with a 42 % lower risk of developing CCA, whereas DPP-4I group was not associated with an increased risk.

Conclusions

GLP-1RAs and DPP-4Is were not associated with a significantly increased risk of CCA. GLP-1RAs even showed a reduced risk of CCA development. They can be considered as safe and effective treatment options for patients with T2DM at risk of CCA.
目的研究美国增量素类药物[胰高血糖素样肽-1 受体激动剂 (GLP-1RA)、二肽基肽酶-4 抑制剂 (DPP-4Is)]的使用与胆管癌 (CCA) 风险之间的关系。方法这项基于人群的大型回顾性队列研究使用 TriNetX 数据集，纳入了 2010 年至 2021 年间新使用 GLP-1RAs、DPP-4Is 或其他二线或三线抗糖尿病药物的 2 型糖尿病 (T2DM) 成年患者。结果共纳入 3,816,071 名患者（平均年龄 61.4 岁，女性占 49.3%）。与二线或三线新用户相比，使用 GLP-1RAs（危险比为 0.49；95 % CI 为 0.40-0.60）和 DPP4Is（危险比为 0.77，95 % CI 为 0.67-0.90）1 年后，CCA 风险分别降低了 51 % 和 23 %。随访 3 年、5 年和 7 年的结果一致（GLP-1RAs 分别为 0.66、0.71 和 0.72，DPP-4Is 分别为 0.84、0.87 和 0.85）。与二甲双胍新使用者相比，GLP-1RA 使用者罹患 CCA 的风险降低了 42%，而 DPP-4I 使用者罹患 CCA 的风险并没有增加。结论GLP-1RAs和DPP-4Is与CCA风险的明显增加无关，GLP-1RAs甚至降低了CCA的发病风险。对于有 CCA 风险的 T2DM 患者来说，这两种药物可被视为安全有效的治疗选择。
{"title":"Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study","authors":"Arunkumar Krishnan ,&nbsp;Carolin V. Schneider ,&nbsp;Hendrik-Tobias Arkenau ,&nbsp;Ezequiel Matias Mauro ,&nbsp;Alejandro Forner ,&nbsp;W. Scott Butsch ,&nbsp;Declan Walsh ,&nbsp;Saleh A. Alqahtani","doi":"10.1016/j.jcte.2024.100370","DOIUrl":"10.1016/j.jcte.2024.100370","url":null,"abstract":"<div><h3>Aim</h3><div>To examine the association between the use of incretin-based drugs [glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4Is)] and the risk of cholangiocarcinoma (CCA) in the United States.</div></div><div><h3>Methods</h3><div>This large population-based, retrospective cohort study using the TriNetX datasets included adult patients with type 2 diabetes mellitus (T2DM) who were new users of GLP-1RAs, DPP-4Is, or other second- or third-line antidiabetic drugs between 2010 and 2021. The primary outcome was the incidence of CCA.</div></div><div><h3>Results</h3><div>A total of 3,816,071 patients were included (mean age, 61.4 years, female, 49.3 %). A 51 % and 23 % risk reduction in CCA after 1 year of exposure to GLP-1RAs (hazard ratio 0.49; 95 % CI 0.40–0.60) and DPP4Is (0.77, 95 % CI 0.67–0.90), respectively compared to new second-or third-line users. Results were consistent at 3, 5, and 7 years of follow-up (0.66, 0.71, and 0.72 for GLP-1RAs and 0.84, 0.87, and 0.85 for DPP-4Is, respectively). Compared to new metformin users, GLP-1RA users were associated with a 42 % lower risk of developing CCA, whereas DPP-4I group was not associated with an increased risk.</div></div><div><h3>Conclusions</h3><div>GLP-1RAs and DPP-4Is were not associated with a significantly increased risk of CCA. GLP-1RAs even showed a reduced risk of CCA development. They can be considered as safe and effective treatment options for patients with T2DM at risk of CCA.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"38 ","pages":"Article 100370"},"PeriodicalIF":4.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142320285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges of using telemedicine for patients with diabetes during the COVID-19 pandemic: A scoping review 在 COVID-19 大流行期间为糖尿病患者使用远程医疗所面临的挑战：范围审查
IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM
Journal of Clinical and Translational Endocrinology
Pub Date : 2024-09-01 Epub Date: 2024-07-14 DOI: 10.1016/j.jcte.2024.100361
Fatemeh Mirasghari , Haleh Ayatollahi , Farnia Velayati , Arezoo Abasi

Background

Telemedicine has aided patients with diabetes during the COVID-19 pandemic in receiving better healthcare services. However, despite its numerous benefits, the use of this technology has faced several challenges. This study aimed to identify the challenges of using telemedicine for patients with diabetes during the COVID-19 pandemic.

Methods

This scoping review was conducted in 2024. Relevant articles published between 2020 and 2023 were searched in databases including PubMed, Scopus, Web of Science, ProQuest, and the Cochrane Library. Initially, 822 articles were retrieved, and after screening 21 articles were selected.

Results

The challenges of using telemedicine for patients with diabetes during the COVID-19 pandemic were categorized into the clinical, individual, organizational, and technical challenges. The clinical challenges included the lack of physical examinations and unavailability of patients’ medical history. The individual challenges contained difficulties in using smart phones by patients and their low level of literacy. The organizational challenges were related to insufficient laws about obtaining patient consent and limited reimbursement for telemedicine services, and the technical challenges included limited access to the high-speed Internet services and inadequate technical infrastructure for telemedicine services. Most studies highlighted the role of individual and organizational challenges in using this technology.

Conclusions

Considering the numerous challenges experienced in using telemedicine for patients with diabetes during the COVID-19 pandemic, it seems that more attention should be paid to address each of these challenges to improve the actual usage, service quality, and user acceptance of telemedicine technology. This, in turn, can lead to saving costs and improving the health status and quality of life of patients with diabetes.

背景在 COVID-19 大流行期间，远程医疗帮助糖尿病患者获得了更好的医疗服务。然而，尽管这项技术好处多多，但其使用也面临着一些挑战。本研究旨在确定在 COVID-19 大流行期间糖尿病患者使用远程医疗所面临的挑战。在 PubMed、Scopus、Web of Science、ProQuest 和 Cochrane Library 等数据库中检索了 2020 年至 2023 年间发表的相关文章。结果在 COVID-19 大流行期间为糖尿病患者使用远程医疗所面临的挑战分为临床挑战、个人挑战、组织挑战和技术挑战。临床挑战包括缺乏体格检查和无法获得患者病史。个人挑战包括患者使用智能手机的困难以及他们的文化水平较低。组织方面的挑战与获得患者同意的法律不健全和远程医疗服务的报销额度有限有关，技术方面的挑战包括高速互联网服务的接入有限和远程医疗服务的技术基础设施不足。结论考虑到在 COVID-19 大流行期间糖尿病患者在使用远程医疗过程中遇到的诸多挑战，似乎应更多地关注如何应对这些挑战，以提高远程医疗技术的实际使用率、服务质量和用户接受度。这反过来又可以节约成本，改善糖尿病患者的健康状况和生活质量。
{"title":"Challenges of using telemedicine for patients with diabetes during the COVID-19 pandemic: A scoping review","authors":"Fatemeh Mirasghari ,&nbsp;Haleh Ayatollahi ,&nbsp;Farnia Velayati ,&nbsp;Arezoo Abasi","doi":"10.1016/j.jcte.2024.100361","DOIUrl":"10.1016/j.jcte.2024.100361","url":null,"abstract":"<div><h3>Background</h3><p>Telemedicine has aided patients with diabetes during the COVID-19 pandemic in receiving better healthcare services. However, despite its numerous benefits, the use of this technology has faced several challenges. This study aimed to identify the challenges of using telemedicine for patients with diabetes during the COVID-19 pandemic.</p></div><div><h3>Methods</h3><p>This scoping review was conducted in 2024. Relevant articles published between 2020 and 2023 were searched in databases including PubMed, Scopus, Web of Science, ProQuest, and the Cochrane Library. Initially, 822 articles were retrieved, and after screening 21 articles were selected.</p></div><div><h3>Results</h3><p>The challenges of using telemedicine for patients with diabetes during the COVID-19 pandemic were categorized into the clinical, individual, organizational, and technical challenges. The clinical challenges included the lack of physical examinations and unavailability of patients’ medical history. The individual challenges contained difficulties in using smart phones by patients and their low level of literacy. The organizational challenges were related to insufficient laws about obtaining patient consent and limited reimbursement for telemedicine services, and the technical challenges included limited access to the high-speed Internet services and inadequate technical infrastructure for telemedicine services. Most studies highlighted the role of individual and organizational challenges in using this technology.</p></div><div><h3>Conclusions</h3><p>Considering the numerous challenges experienced in using telemedicine for patients with diabetes during the COVID-19 pandemic, it seems that more attention should be paid to address each of these challenges to improve the actual usage, service quality, and user acceptance of telemedicine technology. This, in turn, can lead to saving costs and improving the health status and quality of life of patients with diabetes.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"37 ","pages":"Article 100361"},"PeriodicalIF":4.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000322/pdfft?md5=590a27b9957d44dd1050d6802796d361&pid=1-s2.0-S2214623724000322-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141622727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Journal of Clinical and Translational Endocrinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1